Developer of mammalian cell engineering software designed to accelerate the design and manufacture of biologics and gene
Developer of mammalian cell engineering software designed to accelerate the design and manufacture of biologics and gene therapies.
Other Healthcare Technology Systems📍 Boston, MAFounded 2017
Current Valuation
$1.2B
as of 2023-Q1
UNICORN
QL Price
$943.25M
-6% vs last round
QuantLogix's current estimate for Asimov, published 2026-09-08 — below the last disclosed round of $1.0B (2026-02).
Confidence
medium
Basis
secondary led
What backs this price
Last disclosed round
$1.0B
2026-02
weight 0.66
Secondary market print
$885M
2026-06-27
weight 0.64
How this price has held up
No round has priced for Asimov since QuantLogix began publishing a price for it, so there is nothing to grade yet. The claim above is on the record from 2026-09-08 and will be graded against the next priced round. See the full accuracy record →
Which publicly-traded funds already hold it, what $10,000 buys, and whether any route is open to you.
Cite this price as QuantLogix QL Price, Asimov, 2026-09-08 (7def3cfe9e9c0644).
The id pins this exact claim, so a citation stays checkable after the price moves.
Model estimate for research — not a quote, target price, or investment advice.
IPO Outlookprivate
Is Asimov going public?
No. Asimov is private and has not filed to go public. There is no S-1 on file.
What is Asimov's valuation in 2026?
Asimov is valued at $1.2B as of 2023-Q1, set by its Series B ($175M, Jan 2023). That is the last confirmed mark, not a live price — private shares do not trade continuously.
Has Asimov filed an S-1?
No public S-1 is on file for Asimov.
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.
Company Profile
Founded
2017
HQ
Boston, MA
Employees
116
Total Raised
$204.7M
Last Round
Series B — $175M (Jan 2023)
IPO Status
private
Fundraising Status
Series B · $175M · 3y 8mo ago
privateTotal raised $204.7M
Secondary Market
Implied price / share
$82
Last round price / share
$92.68
vs last round
-11.5%
Open interest
1
Last round price vs secondary price
Secondary price return by period
Implied per-share price from private secondary transactions, as of Jun 2026. This is a point estimate, not a quote — the feed carries no bid, ask or spread, and a secondary print is evidence of what someone paid on that date rather than a live market. Compare across every tracked name →
Latest Funding Round
Round
Amount
Date
Lead Investor
Post-Money
Series B
$175M
Jan 2023
—
$1.2B
Vertical Intelligence — Biotech / Gene Therapy
No name-verified sponsor record on ClinicalTrials.gov for Asimov — trials may run under a different legal entity, a partner sponsor, or not yet exist. Absence of a registry match is reported as-is, never guessed around.
Checked clinicaltrials.gov as of 2026-09-03. Re-checked weekly.
Talent Signal
Hiring trend
● First snapshot
trend accrues with monthly sweeps
Open roles
5
via ashby
Product-build share
100%
engineering, research, product, design
Trajectory
steady
heavy product build — 100% of open roles are product-building functions (engineering/research/product) — 4 of 5 open roles are research.
Actively hiring with no tracked executive churn.
Open roles by month
Open roles by function
■ product-building ■ go-to-market / G&A
Staff Software EngineerSenior Scientist, Biologics Cell Line DevelopmentPrincipal Scientist, Biologics Cell Line DevelopmentSenior Associate Scientist, Viral Vector Cell Line Development (Contractor)Research Associate, Cell Line Development (Contractor)
Counted from Asimov's live job board as of 2026-08-17; role functions classified from posting titles. Open-role counts are an activity signal, not headcount. Refreshed monthly.
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of 2023-Q1. Refreshed quarterly.